新華滙富

25 November 2025

Hong Kong & China Market Daily

What's Hot Today:

► WeRide (800 HK, HK\$20.52, HK\$21.1bn): Robotaxi Commercialization Inflection

WeRide focuses on developing and commercializing Level 4 (L4) autonomous driving solutions. Its full-stack L4 system powers Robotaxi, Robobus and other L4 products, with scaled deployments across major cities in China and overseas markets including the Middle East and Europe. Backed by multi-country regulatory approvals and large real-world data sets, WeRide is advancing safe driverless mobility at scale.

Total revenue reached RMB171.0mn in 3Q25 (YoY +144.3%), sustaining a strong growth momentum.

- 1). Product revenue rose to RMB79.2mn (+428% YoY), primarily driven by the accelerated commercial rollout of Robotaxi and Robobus fleets across overseas markets (notably the Middle East) and major domestic cities (e.g., Beijing, Guangzhou and Shenzhen). As WeRide delivered and sold more vehicles equipped with its full-stack L4 autonomous driving system, product revenue base expanded rapidly, with revenue from Robotaxi soaring 761% YoY to RMB35.3mn to account for 20.7% of total revenue (5.8% in 3Q24).
- 2). Service revenue increased to RMB91.8mn (+66.9% YoY), thanks to higher demand for intelligent data services as fleet partnerships scaled up, and expanding multi-city operations that generated more recurring technical support and system service fees.

3Q25 GPM rose sharply to an industry-leading 32.9% from 6.5% in 3Q24 due to economies of scale and the increase of higher margin ADAS R&D services.

Fig 1: Total Revenue (RMB Thousands)

	■ Product	Revenue		Service Re	venue	Tota	al Revenue	. —	YoY Grow	th
Unit: RM	B Thound	S								2000/
200,000										200% 150%
150,000										100%
										50%
100,000										0%
50.000										-50%
50,000										-100% -150%
-										-200%
	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	

			25	N	oven	nber	2025
China & F	IK Ind	ices			CLOSE	1D	YTD
HSI					25,716	2.0%	28.2%
HSCEI					9,079	1.8%	24.5%
HSCCI					4,198	1.0%	11.0%
CSI300					4,448	-0.1%	13.0%
Shanghai A					4,023	0.0%	-5.9%
Shanghai B					251	0.9%	-5.9%
Shenzhen A					2,501	0.9%	22.2%
Shenzhen B					1,277	-0.2%	5.3%
					,		
Key Int'l	Indice	s			CLOSE	1D	YTD
Dow Jones					46,448	0.4%	9.2%
S&P 500					6,705	1.5%	14.0%
Nasdaq					22,872	2.7%	18.4%
NIKKE Index	(48,898	0.6%	22.6%
FTSE Index					9,534	-0.1%	16.7%
CAC Index					7,959	-0.3%	7.8%
DAX Index					23,239	0.6%	16.7%
Commodi	ties				CLOSE	1D	YTD
GOLD		(US\$/oz.)			4,136	1.8%	57.6%
STEEL		(US\$/oz.)			2,338	2.9%	30.9%
SILVER		(US\$/oz.)			51	2.7%	77.1%
CRUDE OIL		(US\$/bbl)			58	1.3%	-18.0%
COPPER	(US\$/oz.)				10,773	0.3%	22.9%
ALUMINIUM		(US\$/oz.)			2,812	-0.1%	10.2%
PLATINUM		(US\$/oz)			1,553	2.1%	70.6%
ZINC		(US\$/oz.)			3,000	-0.5%	0.7%
WHEAT		(US¢/bu)			522	-0.9%	-5.3%
CORN		(US¢/bu)			436	-0.2%	-4.1%
SUGAR		(US¢/lb)			N/A	N/A	
SOYBEAN		(US¢/bu)			1,123	0.1%	8.7%
PVC		(US\$/t.)			N/A	N/A	-18.9%
CRB					295	-0.6%	3.0%
BDI							128.2%
Exchange	Rate	s					
	USD	HKI		EUR	JPY	CHF	RMB
USD		7.782	2 0.	868	156.890	0.809	7.103
HKD	0.129		0.	112	20.165	10.389	0.913
EUR	1.152	8.96	5		180.760	1.074	8.188
JPY	0.006	4.959	0.	553		0.515	0.045
CHF	1.237	9.626	3 1.	074	194.064		8.791
RMB	0.141	1.096	6 0.	122	22.075	0.114	
Market S					Cl	JRRENT	5D
CDS Monitor	- USD	SR 5Y					
Greece						N/A	N/A
Iroland						02	2.40/




Fig 2: Breakdown of Gross Profit Margin (RMB bn)



Source: Company Data, Sunwah Kingsway Research

OPEX Leverage Lifts Profit: The OPEX ratio fell sharply to 255% in 3Q25 from 1,279% in 3Q24, mainly driven by a significant reduction in administrative expenses, which declined from RMB626.0mn to RMB100.4mn. Meanwhile, the Company continued to invest heavily in core technology, with R&D spending rising from RMB254mn to RMB316mn. Supported by strong revenue growth and a leaner cost structure, losses narrowed both YoY and QoQ, with core operating loss and net loss improving to RMB379m and RMB307m, respectively.

Fig 3: Breakdown of OPEX (RMB Thousands)



Source: Company Data, Sunwah Kingsway Research






Fig 4: Breakdown of Core operating profit and Net profit


Source: Company Data, Sunwah Kingsway Research


3Q25 Commercialization Accelerated: WeRide's global rollout stepped up in 3Q25. The Company secured a city-level fully driverless L4 Robotaxi commercial permit in Abu Dhabi, removing the safety-officer requirement, achieving fleet unit-economics breakeven, and launching on Uber. Public operations began in Saudi Arabia and Belgium, while Zurich granted Switzerland's first passenger-carrying driverless Robotaxi permit; testing also progressed in Dubai and Singapore. Fleet size rose to 1,600+, including approximately 750 robotaxis. Fully driverless trips in Guangzhou and Beijing increased by 4 to 8x QoQ, with up to 23 to 25 trips per robotaxi per day. Robobus services in Guangzhou surpassed 1mn passengers and won a new 100-unit order. The Bosch co-developed one-stage end-to-end L2+ ADAS solution also reached Start of Production and entered mass-production deployment.


Our View: 3Q25 results confirms WeRide's commercialization inflection, with Robotaxi revenue accelerating and commercial success in overseas markets. Looking ahead, the company is seeking to increase its order book and ride volume to offset heavy R&D and lower unit costs through scale. With the competitive landscape still fragmented despite clear leaders (including WeRide and Baidu Apollo Go), we are positive on the company's prospects, but the adoptability of its technology in new markets would determine its pace to profitability. The counter is trading at 11.2x FY26E EV/Revenue. (Research Department)




Market Watch - Major Commodities and Currencies


















Source: Bloomberg



US Economic Calendar

			Expected
Indicators	Freq	Obs Date	Release Date
PPI	MoM		25-Nov-25
Business Inventories	MoM		25-Nov-25
Retail Sales	MoM		25-Nov-25
Consumer Confidence	MoM		25-Nov-25
Initial Jobless Claims	WoW		26-Nov-25
Durable Goods Orders	MoM		26-Nov-25
Wholesale Inventories	MoM		1-Dec-25
Housing Starts / Building Permits	MoM		1-Dec-25
New home Sales	MoM		1-Dec-25
ISM Manufacturing PMI	MoM		1-Dec-25
Factory Orders	MoM		1-Dec-25
Industrial Production	MoM		3-Dec-25
Trade Balance	MoM		5-Dec-25
Personal Income & Spending	MoM		5-Dec-25
Employment Report	MoM		16-Dec-25
CPI	MoM		18-Dec-25
Existing Home Sales	MoM		19-Dec-25
GDP	QoQ		23-Dec-25
Auto Sales	MoM		

China Economic Calendar

			Expected
Indicators	Freq	Obs Date	Release Date
PMI Manufacturing	MoM		30-Nov-25
Foreign Exchange Reserves	QoQ		7-Dec-25
Trade Balance	MoM		8-Dec-25
Money Supply - M2	MoM		9-Dec-25
PPI	MoM		10-Dec-25
CPI	MoM		10-Dec-25
Retail Sales	MoM		15-Dec-25
Industrial Production	MoM		15-Dec-25
GDP	YoY		

Hong Kong Economic Calendar

Indicators	Freq	Obs Date	Expected Release Date
Trade Balance	MoM		25-Nov-25
Money Supply - M2	MoM		28-Nov-25
Retail Sales	MoM		1-Dec-25
PMI	MoM		3-Dec-25
Foreign Currency Reserve	MoM		5-Dec-25
Producer Prices Index	QoQ		15-Dec-25
Industrial Production	QoQ		15-Dec-25
Unemployment Rate	MoM		16-Dec-25
CPI	MoM		22-Dec-25
GDP	QoQ		30-Jan-26
Composite Interest Rate	MoM		

Kingsway Research Team

Howard Wong Ensley Liu Email
Howard.wong@sunwahkingsway.com
Ensley.liu@sunwahkingsway.com

Phone No. (852) 2283 7307 (852) 2283 7618



Notice of interest disclosure filed by substantial shareholders f Name of listed corporation	Name of substantial share holder	No. of shares bought/sold/involved	Average price per share
SPC Pharmaceutical Group Ltd.	Cai Dong Chen	14,866,000(L)	HKD 7.4608
hanghai Bio-heart Biological Technology Co., Ltd B - H Shares	Wang Philip Li	10,000(L)	HKD 6.1200
	Winning Pow erful Limited	10,000(L)	HKD 6.1200
ichuan Kelun-Biotech Biopharmaceutical Co., Ltd B - H Sh - H Shares		1,143(L)	HKD 432.8600
ichuan Kelun-Biotech Biopharmaceutical Co., Ltd B - H Sh - H Shares		30,300(L)	HKD 432.7900
ichuan Kelun-Biotech Biopharmaceutical Co., Ltd B - H Sh - H Shares		. , ,	HKD 431.5900
	次即行じ間川行び有収公司 Chen Fei	756,000(L)	
SB Inc.		150,000(L)	HKD 6.7500
dtiger Corporations Ltd.	CASE BLUE LIMITED	29,000,000(L)	HKD 0.1100
dtiger Corporations Ltd.	CASE HOLDINGS GROUP LIMITED	29,000,000(L)	HKD 0.1100
dtiger Corporations Ltd.	YANG WEI	29,000,000(L)	HKD 0.1100
.PT Electronics Co., Ltd H Shares	XIAO Guow ei David	80,000(L)	HKD 2.8700
hina Minsheng Banking Corp., Ltd H Shares	Central Huijin Investment Ltd.	9,505,000(L)	HKD 4.2474
China Minsheng Banking Corp., Ltd H Shares	China Great Wall AMC (International) Holdings Company Limited	9,505,000(L)	HKD 4.2474
China Minsheng Banking Corp., Ltd H Shares	China Great Wall Asset Management Co., Ltd. 中国长城资产管理股份不	9,505,000(L)	HKD 4.2474
SPC Pharmaceutical Group Ltd.	Cai Dong Chen	30,000,000(L)	HKD 7.3791
	Albert Yeung Watch & Jew ellery Group Holdings Limited	7,270,000(L)	HKD 0.2686
mperor Watch & Jew ellery Ltd.	Emperor Watch & Jew ellery Group Holdings Limited	7,270,000(L)	HKD 0.2686
	Luk Siu Man Semon		HKD 0.2686
		7,270,000(L)	
mperor Watch & Jew ellery Ltd.		7,270,000(L)	HKD 0.2686
mperor Watch & Jew ellery Ltd.	Yeung Cindy	270,000(L)	HKD 0.2700
	Yeung Sau Shing, Albert	7,270,000(L)	HKD 0.2686
Glorious Sun Enterprises Ltd.	Yeung Chun Kam	40,000(L)	HKD 1.3500
Cintor Pharmaceutical Ltd B	HUA YUAN INTERNATIONAL LIMITED	30,487,500(L)	HKD 1.6400
intor Pharmaceutical Ltd B	KT International Investment Limited	150,000(L)	HKD 2.0200
	Tong Youzhi	150,000(L)	HKD 2.0200
intor Pharmaceutical Ltd B	中新苏州工业园区创业投资有限公司	30,487,500(L)	HKD 1.6400
Kintor Pharmaceutical Ltd B	苏州元禾控股股份有限公司	30,487,500(L)	HKD 1.6400
intor Pharmaceutical Ltd B	苏州工业园区管理委员会	30,487,500(L)	HKD 1.6400
intor Pharmaceutical Ltd B	苏州工业园区经济发展有限公司	30,487,500(L)	HKD 1.6400
/any Idea Cloud Holdings Ltd.	Liu Jianhui	88,000(L)	HKD 0.5050
/any Idea Cloud Holdings Ltd.	Many Idea Qushuo Limited	88,000(L)	HKD 0.5050
Nany Idea Cloud Holdings Ltd.	Qu Shuo	88,000(L)	HKD 0.5050
, ,	Wang Philip Li	10,000(L)	HKD 6.6200
0 0, -	Winning Pow erful Limited		HKD 6.6200
Shanghai Bio-heart Biological Technology Co., Ltd B - H Shares		10,000(L)	
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd B - H Sh - H Shares	•	2,386(L)	HKD 439.8700
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd B - H Sh - H Shares		63,600(L)	HKD 439.9800
STAR CM Holdings Ltd.	Jin Lei	21,200(L)	HKD 1.1559
STAR CM Holdings Ltd.	Tian Ming	21,200(L)	HKD 1.1559
'eahka Ltd.	Brocade Creation Investment Limited	49,600(L)	HKD 7.5427
eahka Ltd.	Creative Brocade International Limited	49,600(L)	HKD 7.5427
	LIU YINGQI	49,600(L)	HKD 7.5427
	LUO HAIYING	49,600(L)	HKD 7.5427
	Prize Investment Limited		HKD 0.2110
/ik Wo International Holdings Ltd.		32,000,000(L)	
	Xu Liping	32,000,000(L)	HKD 0.2110
'ik Wo International Holdings Ltd.	Xu Youjiang	32,000,000(L)	HKD 0.2110

Source: HKEx



Disclaimer

This document is not an offer to sell or the solicitation of an offer to buy or subscribe for any securities. The securities referred to in this document may not be eligible for sale in certain jurisdiction. Neither this document nor any portion hereof may be taken distributed or transmitted directly or indirectly into such jurisdiction nor to any residents thereof. Any failure to comply with this restriction may constitute a violation of the applicable laws and regulations and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. This document has been produced for private circulation and may not be copied, photocopied, duplicated, or redistributed without the prior written consent of Kingsway Financial Services Group Limited ("KFS") and its affiliated companies (collectively, "Kingsway Group").

This report is distributed in Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") by KFS which is registered as a licensed corporation under the Securities and Futures Ordinance (Cap.571 of The Laws of Hong Kong) with the Securities and Futures Commission of Hong Kong ("SFC") and its SFC CE number is ADF346.

The information contained in this report has been taken from sources believed to be reliable but no representation or warranty expressed or implied is made as to their accuracy or correctness. This report is published for the assistance of recipients but is not to be relied upon as authoritative or taken in substitution for the exercise of judgment by any recipient. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities of the company or companies covered herein. Any recommendation contained in this report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. All opinions and estimates reflect our judgment on the date of this report and are subject to change without notice.

KFS, including its parent, subsidiaries and/or affiliates, may act as lead or co-manager in an offering of the securities of any issuer discussed herein, may from time to time perform financial services or other advisory services for, or solicit financial services or other business from, any issuer.

Within the past year, KFS, including its parent, subsidiaries and/or affiliates, may have acted as market maker or traded on a principal basis in the financial instruments of any issuer discussed herein and may act as underwriter, placement agent, advisor or lender to such issuer.

KFS, including its parent, subsidiaries, affiliates, shareholders, officers, directors, and employees may have long or short positions in, and buy or sell, the securities, commodities or derivatives (including options) or any other financial instruments thereof, of any issuers.

An employee of KFS, including its parent, subsidiaries and/or affiliates, may act as director, or be represented on the boards of directors, of any such entities or issuers.

Copyright 2025 Kingsway Group. All rights reserved.

Head	Office
------	--------

Hong Kong Kingsway Financial Services Group Limited 7/F, Tower One, Lippo Centre, 89 Queensway, Hong Kong Tel: 852-2283-7000

Fax: 852-2877-2665

Affiliated & Overseas Offices

Guangdong 廣東新華滙富商業保理有限公司 2701, Dongshan Plaza, 69 Xianlie Middle Road, Yuexiu District Guangzhou, 510095 Vietnam Sunwah Kingsway Vietnam Services Limited Representative Office Sunwah Tower, Mezzanine Floor 115 Nguyen Hue District 1 Ho Chi Minh City Vietnam